Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Tumors with a high level of TILs also have high expression of PD-L1, "but PD-L1-negative tumors ... nodes followed by the licensing of lymphatic cells that circulate back to the area of ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Immunotherapy has transformed cancer treatment, offering new avenues of hope for patients with advanced disease or limited ...

Our Bureau, Mumbai Thursday, December 26, 2024, 16:40 Hrs [IST] ...

Drug used to treat non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and ...